A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Mupirocin Calcium Cream, 2% and Reference Listed Bactroban® Cream (Mupirocin Calcium Cream, 2%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions.

Taro Pharmaceuticals USA0 sites1,902 target enrollmentFebruary 2013

ConditionsSecondarily Infected Traumatic Skin Lesions

InterventionsBactroban® Cream Mupirocin Calcium Cream, 2%Cream vehicle of test product

DrugsMupirocin Calcium Cream, 2%Bactroban® Cream Cream vehicle of test product

Overview

Phase: Phase 1
Intervention: Bactroban® Cream
Conditions: Secondarily Infected Traumatic Skin Lesions
Sponsor: Taro Pharmaceuticals USA
Enrollment: 1902
Primary Endpoint: Clinical cure at visit 4
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The primary objective of this study is to determine the comparability of the safety and efficacy of Mupirocin Calcium Cream, 2% and Bactroban® Cream in subjects with secondarily infected traumatic skin lesions. It will also be determined whether the efficacy of each of the active treatments is superior to that of the vehicle cream (placebo).

Registry

clinicaltrials.gov

Start Date

February 2013

End Date

May 6, 2019

Last Updated

6 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Taro Pharmaceuticals USA

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy male or nonpregnant females aged 18 months or older with a secondarily infected traumatic skin lesion such as a laceration, sutured wound, or abrasion.
•The laceration or sutured wound should not exceed 10 cm in length with surrounding erythema not more than 2 cm from the edge of the lesion. An abrasion should not exceed 100 cm2 in total area with surrounding erythema not more than 2 cm from the edge of the abrasion.
•Positive baseline culture for S. aureus and/or S. pyogenes from a sample taken from the secondarily infected traumatic skin lesion.
•Positive Gram stain or Wright stain for confirmation of white blood cells in the pus/exudate from the secondarily infected traumatic skin lesion.
•Skin Infection Rating Scale total score for the secondarily infected traumatic skin lesion of at least 8 at baseline.
•Women of childbearing potential, in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control during the study. Subjects entering the study who are on hormonal contraceptives must have been on the method for at least 90 days prior to the study and continue the method for the duration of the study. Subjects who had used hormonal contraception and stopped must have stopped no less than 90 days prior to the study.
•Subjects 18 years of age or older must provide Institutional Review Board approved written informed consent. Subjects under the age of 18 years must have parent or legal guardian provide Institutional Review Board approved written consent. An assent form for minors must be completed for subjects under the legal age of consent, depending on the age range required by state laws.
•Subjects must be willing and able to understand and comply with the requirements of the study, apply the medication as instructed, return for the required study visits, comply with therapy prohibitions, and be able to complete the study.
•Subjects must be in good health and free from any clinically significant disease, other than secondarily infected traumatic skin lesions, that might interfere with the study evaluations.

Exclusion Criteria

•Subjects who are pregnant, nursing, or planning a pregnancy within the study participation period.
•Any dermatological disorder that may interfere with evaluation of the subject's secondarily infected traumatic skin lesion(s).
•Bacterial skin infection that, because of depth or severity, could not be appropriately treated with a topical antibiotic.
•Secondarily infected bite or puncture wound.
•Systemic signs or symptoms of infection.
•Requirement for surgical intervention for treatment of the infection prior to study entry.
•A subject must not have received any topical corticosteroid, topical antibiotic, or antifungal agent for at least 48 hours (2 days) prior to baseline.
•A subject must not have received any systemic antibiotic or systemic corticosteroid for at least 7 days prior to baseline.
•Primary or secondary immunodeficiency.
•Diabetes.

Arms & Interventions

Bactroban® Cream

Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline)

Intervention: Bactroban® Cream

Mupirocin Calcium Cream, 2%

Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.)

Intervention: Mupirocin Calcium Cream, 2%

Cream vehicle of test product

Cream vehicle of test product (Taro Pharmaceuticals Inc.)

Intervention: Cream vehicle of test product

Outcomes

Primary Outcomes

Clinical cure at visit 4

Time Frame: 7 days after end of treatment

The proportion of subjects in each treatment group with clinical cure, defined as an SIRS score of 0 for all signs and symptoms at Visit 4/Follow-up (7 days after the end of treatment).